WebMD’s CEO Redmond Steps Down After 1 Year in Post

WebMD Health Corp. (WBMD)’s Chief Executive Officer Cavan Redmond stepped down today after about a year on the job as the consumer health-information website raised its sales forecast for 2013.

David Schlanger, WebMD’s senior vice president, strategic and corporate development, will take over on an interim basis in the top post as the board seeks a permanent replacement, the New York-based company said in a statement. The company also raised its revenue projection to $450 million to $470 million from $430 million to $455 million, based on an improved outlook for its advertising business from drug companies.

WebMD generates most of its revenue from ads and sponsorships, and said in July that business would probably suffer as drugmakers face patent expirations and delayed products. In December the online provider of health information said it would fire 250 workers, about 14 percent of its workforce, citing the decline in drug ads.

“The change announced today will best position us to build on the momentum that our senior management team has created to date,” said Chairman Martin Wygod. “We will accelerate the development and implementation of strategies to diversify our revenue base and capture opportunities arising form the rapidly changing health-care landscape.”

WebMD’s shares gained 15 percent to $29.24 in extended trading at 6:08 p.m. New York time. The shares have gained 17 percent in the past 12 months.

Deal Talks

Redmond, the former head of animal health, consumer health- care and corporate strategy for Pfizer Inc., was hired about a year ago as CEO. In January 2012, WebMD said it broke off talks with potential buyers because the offers were less than the company’s value. Schlanger has been with WebMD and its predecessors for 18 years and was responsible for acquisitions and deals operations.

WebMD also today reported its first-quarter net loss narrowed to $1.54 million, or 3 cents a share, from $7.78 million, or 14 cents, a year earlier. Analysts had estimated a loss of 15 cents, according to the average of five estimates compiled by Bloomberg. Sales were $113 million, compared with analysts’ estimates of $107 million.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.